NASDAQ:PRTA
Prothena Corporation plc Stock News
$22.52
-0.87 (-3.72%)
At Close: May 17, 2024
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
09:05pm, Thursday, 10'th Feb 2022 GlobeNewswire Inc.
DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
09:05pm, Thursday, 10'th Feb 2022 GlobeNewswire
DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.
Will Prothena (PRTA) Report Negative Q4 Earnings? What You Should Know
08:01pm, Thursday, 03'rd Feb 2022 Zacks Investment Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nikola signs multiyear deal for Proterra battery technology
04:34pm, Tuesday, 18'th Jan 2022
Nikola Corp. has signed a multiyear deal with battery maker Proterra Inc. to use Proterra battery packs in its electric trucks. It is the first Class 8 truck maker to align with Proterra Powered, a ne
Why Jim Cramer Prefers This Mining Stock Over Vale
01:52pm, Thursday, 13'th Jan 2022 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ChargePoint Holdings, Inc. (NYSE: CHPT) is "part of a very challenged group." Following a deep research on the group, he added that there are
Why Jim Cramer Prefers This Mining Stock Over Vale
01:52pm, Thursday, 13'th Jan 2022 Benzinga
On CNBCs "Mad Money Lightning Round," Jim Cramer said ChargePoint Holdings, Inc. (NYSE: CHPT ) is "part of a very challenged group." Following a deep research on the group, he added that there are several players and there has "not been enough consolidation." He recommended avoiding the stock. Cramer said he likes Prothena Corporation plc (NASDAQ: PRTA ) as it has a very positive Alzheimers formulation and other things Full story available on Benzinga.com
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
01:18pm, Thursday, 13'th Jan 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant
Adagio Therapeutics, Inc. (NASD
5 Biotech Stocks That More Than Doubled This Year
01:09pm, Thursday, 23'rd Dec 2021 Zacks Investment Research
The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplar
5 Biotech Stocks That More Than Doubled This Year
09:13am, Thursday, 23'rd Dec 2021
The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplar
-$0.71 EPS Expected for Prothena Co. plc (NASDAQ:PRTA) This Quarter
03:02pm, Tuesday, 14'th Dec 2021 Transcript Daily
Brokerages expect Prothena Co. plc (NASDAQ:PRTA) to announce earnings per share of ($0.71) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Prothena’s earnings, with the highest EPS estimate coming in at ($0.52) and the lowest estimate coming in at ($0.84). Prothena reported earnings per share of ($0.77) in the […]
Hedge Funds Are Crazy About Prothena Corporation plc (PRTA)
08:55pm, Sunday, 12'th Dec 2021 Insider Monkey7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
01:51pm, Tuesday, 07'th Dec 2021
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared
7 A-Rated Biotechs to Buy for the Long Run
11:58am, Friday, 03'rd Dec 2021
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.
Prothena: A Biotech Company With A Promising Pipeline
05:12am, Wednesday, 01'st Dec 2021
Prothena has a drug candidate Birtamimab in phase three trials and is close to approval. The company has a promising pipeline in some high-revenue neurodegenerative disease fields.
Prothena Corporation plc: Prothena to Participate in JMP Securities Hematology and Oncology Summit
09:17pm, Monday, 29'th Nov 2021 FinanzNachrichten
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built o